Rabbit Anti-Human CD240d (a.a. 161-210) Polyclonal antibody

Bacteria capable of simultaneously degrading organic pollutants and resisting heavy metal contamination are vitally important in bioremediation. However, such bacteria are difficult to obtain and our understanding of their potential use in remediation remains limited. Here, using rhd and chrA as gene markers for PAHs-degradation and Cr (VI)-resistance, genome mining revealed that 11.62% of surveyed species contained both rhd and chrA genes. These bacteria were affiliated to 13 phyla in which Pseudomonas, Acinetobacter, Bacillus, Halomonas, Rhizobium, and Burkholderia were the most prominent genera. Culture-dependent isolation and genome-guided functional validation identified two novel phenanthrene (Phe)-degrading and Cr (VI)-tolerant strains, Pseudarthrobacter phenanthrenivorans J015 and Croceicoccus naphthovorans PQ-2(T). J015 showed an extraordinary potential for Phe-Cr (VI) bioremediation. It could completely degrade 100 mgl(-1) Phe within 17 days under 30 mgl(-1) K2Cr2O7 stress, and could be further improved by optimization of cultivation conditions. Quantitative real time PCR (qRT-PCR) analysis showed that Phe or Cr (VI) affected the expression of chrA or rhd genes in J015, respectively. Overall, Phe-degradation and Cr (VI)-resistance by J015 interacted with each other in a complex pattern. Genome-guided prediction and functional validation is a valuable alternative to culture dependent isolation for exploring PAHs-Cr (VI) bioremediation resources.

BACKGROUNDRecent reports have indicated that the risk of anti-D alloimmunization following D-incompatible platelet (PLT) transfusion is low in hematology and oncology patients. We investigated the rate of anti-D alloimmunization in RhD-negative (D-) patients with chronic liver disease transfused with D+ platelet concentrates (PCs) and the factors involved, at a liver transplant (LT) center. STUDY DESIGN AND METHODSWe reviewed the blood bank database from January 2003 to October 2016. D- patients who had received D+ PLT transfusions were eligible if they had undergone antibody screening at least 28 days after the first D+ PC transfusion, had no previous or concomitant exposure to D+ blood products, and had not received anti-D immunoglobulins. RESULTSSix of the 56 eligible patients (10.7%) had anti-D antibodies. All had received whole blood-derived PCs. Four of 20 patients (20%) untransplanted or transfused before LT and only two of 36 patients (5.6%) transfused during or after LT produced anti-D antibodies. These two patients were on maintenance immunosuppression based on low-dose steroids and tacrolimus. The factors identified as significantly associated with anti-D immune response were the presence of red blood cell immune alloantibodies before D+ PLT transfusion (p = 0.003), and D+ PLT transfusion outside the operative and postoperative (5 days) periods for LT (p = 0.023). CONCLUSIOND- patients with chronic liver disease transfused with D+ PLTs before LT are at high risk of developing anti-D antibodies. Preventive measures should be considered for these patients.